Roivant Sciences Ltd. (NASDAQ:ROIV) Receives $18.08 Consensus Price Target from Brokerages

Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) has earned a consensus rating of "Buy" from the seven analysts that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $18.08.

Several research firms recently commented on ROIV. HC Wainwright restated a "buy" rating and set a $18.00 target price on shares of Roivant Sciences in a research report on Tuesday, February 11th. Cantor Fitzgerald upgraded Roivant Sciences to a "strong-buy" rating in a research note on Thursday, January 30th.

Insider Buying and Selling at Roivant Sciences

In other Roivant Sciences news, CAO Rakhi Kumar sold 227,500 shares of the business's stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $10.43, for a total transaction of $2,372,825.00. Following the transaction, the chief accounting officer now owns 163,264 shares of the company's stock, valued at $1,702,843.52. The trade was a 58.22 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, COO Eric Venker sold 100,000 shares of the company's stock in a transaction on Thursday, February 20th. The stock was sold at an average price of $10.65, for a total transaction of $1,065,000.00. Following the sale, the chief operating officer now directly owns 896,869 shares in the company, valued at $9,551,654.85. This trade represents a 10.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 2,388,170 shares of company stock worth $27,612,299. Corporate insiders own 7.90% of the company's stock.

Remove Ads

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in ROIV. FMR LLC lifted its holdings in Roivant Sciences by 0.3% during the 4th quarter. FMR LLC now owns 49,301,583 shares of the company's stock worth $583,238,000 after purchasing an additional 156,527 shares during the last quarter. Vanguard Group Inc. increased its position in Roivant Sciences by 5.8% during the 4th quarter. Vanguard Group Inc. now owns 44,087,287 shares of the company's stock worth $521,553,000 after buying an additional 2,404,232 shares during the period. State Street Corp lifted its holdings in shares of Roivant Sciences by 6.1% during the third quarter. State Street Corp now owns 19,561,249 shares of the company's stock worth $225,737,000 after buying an additional 1,118,561 shares in the last quarter. Patient Square Capital LP boosted its position in shares of Roivant Sciences by 2.1% in the fourth quarter. Patient Square Capital LP now owns 12,480,000 shares of the company's stock valued at $147,638,000 after acquiring an additional 251,535 shares during the period. Finally, Two Seas Capital LP boosted its position in shares of Roivant Sciences by 4.6% in the fourth quarter. Two Seas Capital LP now owns 10,167,807 shares of the company's stock valued at $120,285,000 after acquiring an additional 442,914 shares during the period. 64.76% of the stock is currently owned by institutional investors.

Roivant Sciences Stock Down 0.3 %

NASDAQ ROIV traded down $0.03 during trading on Friday, hitting $10.49. The company's stock had a trading volume of 4,909,737 shares, compared to its average volume of 4,217,937. Roivant Sciences has a 52 week low of $9.76 and a 52 week high of $13.06. The firm has a market cap of $7.49 billion, a P/E ratio of -69.93 and a beta of 1.25. The firm has a 50 day moving average price of $11.14 and a 200 day moving average price of $11.60.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) last released its earnings results on Monday, February 10th. The company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.04. Roivant Sciences had a negative net margin of 119.54% and a negative return on equity of 14.05%. On average, equities analysts expect that Roivant Sciences will post -0.92 earnings per share for the current year.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.